These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 1347016)

  • 1. Protection from lethal graft-vs.-host disease by donor stem cell repopulation.
    Rozendaal L; Pals ST; Melief CJ; Gleichmann E
    Eur J Immunol; 1992 Feb; 22(2):575-9. PubMed ID: 1347016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attempts at standardization of lupus-like graft-vs-host disease: inadvertent repopulation by DBA/2 spleen cells of H-2-different nonirradiated F1 mice.
    Van Rappard-Van Der Veen FM; Radaszkiewicz T; Terraneo L; Gleichmann E
    J Immunol; 1983 Jun; 130(6):2693-701. PubMed ID: 6602176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allosuppressor- and allohelper-T cells in acute and chronic graft-vs-host disease. IV. Activation of donor allosuppressor cells is confined to acute GVHD.
    Pals ST; Radaszkiewicz T; Gleichmann E
    J Immunol; 1984 Apr; 132(4):1669-78. PubMed ID: 6230390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of F1 cytotoxic potentials by GvHR. Host- and donor-derived cytotoxic lymphocytes arise in the unirradiated F1 host spleens under the condition of GvHR-associated immunosuppression.
    Kubota E; Ishikawa H; Saito K
    J Immunol; 1983 Sep; 131(3):1142-8. PubMed ID: 6604089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease.
    Via CS; Sharrow SO; Shearer GM
    J Immunol; 1987 Sep; 139(6):1840-9. PubMed ID: 2957440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effect of murine cytomegalovirus on the induction of acute graft-vs-host disease involving MHC class I differences only. Analysis of in vitro T cell function.
    Via CS; Shanley JD; Shearer GM
    J Immunol; 1990 Nov; 145(10):3283-9. PubMed ID: 2172381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unexpected role of TNF-alpha in graft versus host reaction (GVHR): donor-derived TNF-alpha suppresses GVHR via inhibition of IFN-gamma-dependent donor type-1 immunity.
    Yamamoto S; Tsuji T; Matsuzaki J; Zhange Y; Chamoto K; Kosaka A; Togashi Y; Sekikawa K; Sawada K; Takeshima T; Koike T; Nishimura T
    Int Immunol; 2004 Jun; 16(6):811-7. PubMed ID: 15126416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosuppression of B cells in vitro by graft-vs.-host reaction-derived T cells is caused by cytotoxic T lymphocytes.
    Rozendaal L; Pals ST; Schilham M; Melief CJ; Gleichmann E
    Eur J Immunol; 1989 Sep; 19(9):1669-75. PubMed ID: 2792183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of L3T4+ and Lyt-2+ donor cells in graft-versus-host immune deficiency induced across a class I, class II, or whole H-2 difference.
    Moser M; Sharrow SO; Shearer GM
    J Immunol; 1988 Apr; 140(8):2600-8. PubMed ID: 3258615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lethal graft-vs-host disease induced by a class II MHC antigen only disparity is not mediated by cytotoxic T cells.
    Thiele DL; Bryde SE; Lipsky PE
    J Immunol; 1988 Nov; 141(10):3377-82. PubMed ID: 3053897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of CD4+ and CD8+ lymphocyte subsets by streptozotocin in the popliteal lymph node assay. II. Comparison with acute graft-vs-host reaction in H-2 incompatible F1 mouse hybrids.
    Krzystyniak K; Panaye G; Descotes J; Revillard JP
    Immunopharmacol Immunotoxicol; 1992; 14(4):865-82. PubMed ID: 1363474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lethal graft-vs-host disease across major histocompatibility barriers: requirement for leucyl-leucine methyl ester sensitive cytotoxic T cells.
    Thiele DL; Charley MR; Calomeni JA; Lipsky PE
    J Immunol; 1987 Jan; 138(1):51-7. PubMed ID: 2946780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DBA/2J and DBA/2Ha lymphocytes differ in their ability to induce graft-vs-host disease.
    Fast LD
    J Immunol; 1989 Oct; 143(8):2489-93. PubMed ID: 2794505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of F1 cytotoxic potentials by GvHR: role and mode of action of non-MHC genes that determine the hybrid resistance to GvHR-associated suppression of F1 cytotoxic potential.
    Ishikawa H; Kubota E; Saito K
    J Immunol; 1984 May; 132(5):2218-25. PubMed ID: 6232314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of T cell subsets in lethal graft-versus-host disease (GVHD) directed to class I versus class II H-2 differences. II. Protective effects of L3T4+ cells in anti-class II GVHD.
    Sprent J; Schaefer M; Korngold R
    J Immunol; 1990 Apr; 144(8):2946-54. PubMed ID: 1969878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of graft-versus-host disease on anti-tumor immunity.
    Schreiber KL; Forman J
    J Immunol; 1990 Mar; 144(5):2018-26. PubMed ID: 1968493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depletion of asialo-GM1+ cells from the F1 recipient mice prior to irradiation and transfusion of parental spleen cells prevents mortality to acute graft-versus-host disease and induction of anti-host specific cytotoxic T cells.
    Varkila K
    Clin Exp Immunol; 1987 Sep; 69(3):652-9. PubMed ID: 3499271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The target minor H antigen for F1 cytotoxic T lymphocytes induced by Igh-congenic parental spleen cells is coded for by gene linked to H-2.
    Ishikawa H; Kubota E; Suzuki H; Saito K
    J Immunol; 1985 May; 134(5):2953-9. PubMed ID: 2580009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.